DEFA14A: ESSA Pharma to be Acquired by XenoTherapeutics in All-Cash Deal with Contingent Value Rights

ESSA Pharma Inc. has entered into a definitive agreement to be acquired by XenoTherapeutics, Inc., backed by XOMA Royalty Corporation, in an all-cash transaction that includes contingent value rights for shareholders, as ESSA winds down its operations.

Summary

• ESSA Pharma Inc. will be acquired by XenoTherapeutics, Inc., with financing and structuring support from XOMA Royalty Corporation.
• Shareholders will receive a cash payment per common share, currently estimated at approximately $1.91, exclusive of contingent value rights (CVRs).
• Each shareholder will also receive one non-transferable CVR, potentially yielding up to an additional $0.06 per CVR, totaling up to $2,950,000.
• The transaction is structured as a court-approved plan of arrangement under British Columbia law.
• ESSA's Board of Directors unanimously approved the transaction, deeming it in the best interest of the Company and shareholders, as it facilitates the discontinuance and winding-up of ESSA's business.
• The transaction requires approval from at least 66% of votes cast by shareholders, 66% of votes cast by securityholders (including options and pre-funded warrants), and a majority of votes cast by shareholders excluding certain interested parties.
• Directors and senior officers, holding approximately 2.23% of outstanding shares, have entered into voting and support agreements to vote in favor of the transaction.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company is winding down its operations, the transaction provides a structured and expedited return of cash to shareholders, along with potential upside from CVRs, which is presented as a better alternative than a full liquidation. The unanimous board approval and insider support reinforce this positive framing of an exit strategy.

Positives

• Provides a clear path to deliver cash value to shareholders in an expedited timeframe.
• Offers less complexity and value risk compared to a full liquidation process.
• Includes contingent value rights (CVRs) that could provide additional cash payments to shareholders, up to $2,950,000 in total.
• Unanimously approved by ESSA's Board of Directors and Transaction Committee, indicating strong internal support.
• Secures financing and structuring support from XOMA Royalty Corporation, a biotechnology royalty aggregator.

Negatives

• The cash payment per share is an estimate ($1.91) and is subject to deductions for transaction costs, liabilities, legal expenses, and a $4,000,000 transaction fee to Xeno.
• CVR payments are contingent and not guaranteed, with potential for no payment if certain expenses exceed thresholds (e.g., Legacy Expense Amount exceeds $150,000 or Company Litigation Expenses exceed $3,550,000).
• The CVRs are non-transferable, limiting liquidity for shareholders.
• The company is discontinuing its business and winding down operations, indicating a cessation of its previous strategic focus on prostate cancer therapies.

Risks

• Transaction Completion Risk: The transaction is subject to various conditions, including shareholder, regulatory, and court approvals, which may not be obtained on anticipated terms or timing.
• Litigation Risk: Potential litigation relating to the transaction could be instituted against ESSA, Xeno, XOMA Royalty, or their directors/officers, which could impact the transaction or result in additional costs.
• Business Disruption Risk: Disruptions from the transaction could harm ESSA's business, including current plans and operations, during the pendency of the transaction.
• Key Personnel Retention Risk: The ability of ESSA to retain and hire key personnel during the transition period is a risk.
• Adverse Reactions/Business Relationship Changes: Potential adverse reactions or changes to business relationships may result from the announcement or completion of the transaction.
• Financial Projections Accuracy: The accuracy of ESSA's financial projections, which underpin the estimated cash payment, is subject to uncertainties.
• Transaction Costs: Significant transaction costs are associated with the acquisition, which will reduce the cash available for shareholders.
• Higher-than-Anticipated Costs: The transaction may be more expensive to complete than anticipated due to unexpected factors or events.
• Competitive Responses: Competitive responses to the transaction could arise.
• Dissenting Shareholder Risk: If more than 5% of outstanding common shares exercise dissent rights, the transaction may not close.
• CVR Payment Uncertainty: There is no assurance that holders will receive any payments under the CVRs, as payments are contingent on specific financial outcomes and litigation expenses.
• Tax Implications: The tax treatment of CVRs (especially for Equity Award CVRs as compensation) could have implications for holders.

Future Outlook

The document indicates that ESSA Pharma Inc. is discontinuing its business operations, including the termination of clinical trials for masofaniten and withdrawal of its investigational new drug application. The future outlook for the company is a complete wind-down and voluntary dissolution following the acquisition by XenoTherapeutics, with the transaction aiming to provide a final cash distribution and potential contingent value rights to shareholders.

Management Comments

• "After conducting a comprehensive review of the opportunities available to ESSA and considering the communications received from our shareholders, the ESSA Board of Directors has unanimously concluded that entering into this agreement with Xeno and XOMA Royalty is in the best interest of the Company and maximizes value for our shareholders as the Company proceeds with its plans to discontinue operations and wind-down its business."
• "This Transaction delivers cash value to shareholders in an expedited timeframe, with less complexity and value risk when compared to a liquidation, and thus delivers more certain value to shareholders."

Industry Context

This announcement reflects a strategic exit for ESSA Pharma, a company previously focused on prostate cancer therapies, through an acquisition by a non-profit biotechnology company, XenoTherapeutics, with financial backing from a royalty aggregator, XOMA Royalty Corporation. This type of transaction, involving the wind-down of a clinical-stage biotech and a structured return of capital to shareholders, is common when drug development programs do not yield desired results or when a company seeks to avoid the complexities and uncertainties of a full liquidation. It highlights the high-risk, high-reward nature of the biotechnology sector, where companies may pivot or cease operations if their pipeline does not progress as expected. XOMA Royalty's involvement suggests a model where financial entities acquire assets or provide funding in exchange for future economics, which can be a viable option for companies seeking to monetize remaining value or manage an orderly wind-down.

Comparison to Industry Standards

• The estimated cash payment of $1.91 per share, plus potential CVRs, should be compared to the company's cash per share at the time of the announcement and its historical trading price. Without specific cash balance figures in the provided text, a direct comparison to industry peers' liquidation values or acquisition premiums is not possible.
• The use of Contingent Value Rights (CVRs) is a common mechanism in biotech acquisitions, particularly when there is uncertainty around future asset value or potential liabilities (like litigation), allowing sellers to retain some upside while providing buyers with a more defined upfront cost. This structure is similar to those seen in other biotech wind-downs or asset sales where future contingent payments are tied to specific milestones or the resolution of liabilities.
• The 2.23% insider voting support is a positive indicator, aligning management and director interests with the transaction, which is a standard practice in such deals.
• The $2.5 million termination fee is a customary deal protection provision, comparable to those found in similar-sized M&A transactions in the biotech sector, designed to compensate the buyer for expenses and lost opportunity if the deal is terminated under specific circumstances.

Management Changes

Corporate Governance

Legal Proceedings

• The document mentions 'Company Litigation' as a factor affecting CVR proceeds, defined as 'any proceeding against or involving the Company and its directors and/or officers that is either (a) included in the Disclosure Letter or (b) existing as of the date hereof or arising following the date hereof and 18 months following the Closing Date arising from facts or circumstances existing as of the Effective Time.'
• The CVR Committee will control the defense of any Company Litigation, with Purchaser having the option to select co-counsel.
• The document also mentions 'potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty or their respective directors or officers.'

Related Party Transactions

• The Voting and Support Agreements entered into by ESSA's directors and senior officers with the Purchaser are disclosed as related party transactions.
• The document states that, except as disclosed in Company Public Documents, the Company has not made payments/loans to, borrowed from, or been indebted to any Related Party (excluding wholly-owned subsidiaries).
• It also states that, to the Company's knowledge, no management, key employee, executive officer, or director, or their affiliates/associates, directly or indirectly owns interests in or is an officer/employee/consultant to a competitor, lessor, lessee, supplier, distributor, agent, or customer of the Company, or owns property used by the Company, or has claims against the Company (except for liabilities in financial statements and accrued benefits).

Stakeholder Impact

• Shareholders: Will receive an estimated cash payment of $1.91 per share and potential contingent value rights (CVRs) up to $0.06 per CVR, providing a structured and expedited return of capital as the company winds down. This offers more certainty than a full liquidation.
• Employees/Officers: Existing employment agreements, termination, severance, change-of-control, and retention agreements will be honored, and COBRA costs will be covered. Directors and officers will resign upon closing.
• Customers/Suppliers: The company is discontinuing its business, implying cessation of its previous operations, which will impact any existing customer or supplier relationships.
• Creditors: The transaction includes provisions for deducting certain liabilities and legal expenses from the cash balance, and the Purchaser will undertake voluntary dissolution upon satisfaction of all liabilities, indicating a plan for orderly settlement of obligations.
• Regulatory Authorities: The transaction requires various regulatory and court approvals, ensuring oversight of the process.

Next Steps

• ESSA to apply for an interim order from the Supreme Court of British Columbia (no later than August 5, 2025).
• ESSA to make an initial cash distribution to shareholders prior to closing, if authorized by the interim order.
• ESSA to prepare and complete the Circular (information circular and proxy statement) for the Special Meeting.
• ESSA to convene and conduct the Special Meeting to consider the Arrangement Resolution (on or before September 8, 2025, or later if SEC comments extend the deadline).
• If the Arrangement Resolution is passed, ESSA to apply for the Final Order from the Supreme Court of British Columbia (within 5 Business Days after the meeting).
• Closing of the transaction (Effective Date) is expected on the third Business Day following receipt of the Final Order.
• Purchaser to undertake a voluntary dissolution of ESSA following the Effective Time and satisfaction of liabilities.
• Parent to recalculate Final Company Net Cash within 60 days following the Closing Date.
• CVR payments (if any) to be made on CVR Payment Dates (no later than 30 days following final determination of Legacy Liability Adjustment or final resolution of Company Litigation).
• Common Shares to be delisted from Nasdaq and deregistered under the US Exchange Act as promptly as practicable following the Effective Time.

Key Dates

Recommendation

Keywords

ESSA Pharma, XenoTherapeutics, XOMA Royalty Corporation, Acquisition, Merger, Contingent Value Rights, CVR, SEC Filing, Plan of Arrangement, Shareholder Value, Biotechnology, Prostate Cancer, Company Wind-down, Liquidation, Corporate Governance, Financial Reporting, Risk Management, Strategic Business Analysis